Systemic gaps in pediatric neurodiversity care drive interest in cannabis research
Original framing: “Can medicinal cannabis help kids’ autism, ADHD or Tourette’s? Here’s what we know so far” — The Conversation - Global
The original framing omits historical and cultural use of cannabis in traditional medicine, fails to include Indigenous and non-Western perspectives on holistic healing, and neglects the role of environmental and socioeconomic factors in neurodevelopmental conditions. It also ignores the voices of neurodivergent individuals and their lived experiences with alternative therapies.
Medium structural omission detected in mainstream coverage.
This narrative is produced by medical researchers and media outlets for parents and policymakers, framing cannabis as a novel solution rather than a symptom of deeper systemic gaps. The framing serves pharmaceutical and biotech interests by redirecting attention from structural underfunding of neurodiversity support programs. It obscures the role of profit-driven research agendas in shaping public perception of alternative treatments.
Indigenous communities have used cannabis for centuries as part of a holistic health framework that integrates mind, body, and spirit. These traditions emphasize context-specific use and community stewardship, offering a contrast to the pharmaceutical model that dominates Western medicine.
The current discourse on medicinal cannabis for pediatric neurodevelopmental conditions reflects a systemic failure to provide adequate support for neurodivergent children.